INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin Kathryn A. MasonDavid ValdecanasLuka Milas PRECLINICAL STUDIES 13 July 2007 Pages: 1 - 5
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits Vinay BhaskarMelvin FoxVanitha Ramakrishnan Preclinical Studies 01 September 2007 Pages: 7 - 12
Protein kinase C-β inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis Arkadiusz Z. DudekPawel ZwolakFaris Farassati Preclinical Studies 06 September 2007 Pages: 13 - 24
Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity Praveen RajendranManu JaggiAnand C. Burman Preclinical Studies 13 September 2007 Pages: 25 - 34
Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors Catherine DelbaldoEric RaymondSandrine Faivre Phase I Studies 18 September 2007 Pages: 35 - 43
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor Kyle HolenLeonard B. SaltzAxel-Rainer Hanauske Phase I Studies 09 October 2007 Pages: 45 - 51
Prognostic factors among cancer patients with good performance status screened for phase I trials Nicolas PenelMarie VanseymortierJacques Bonneterre PHASE I STUDIES 22 September 2007 Pages: 53 - 58
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors Elisabeth I. HeathKeith BiblePatricia M. LoRusso PHASE I STUDIES 16 October 2007 Pages: 59 - 65
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study Emilio EstebanNoemi VillanuevaAngel Jiménez-Lacave PHASE II STUDIES 05 September 2007 Pages: 67 - 74
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC) Joseph G. KattanFady S. FarhatCancer Research Group PHASE II STUDIES 06 September 2007 Pages: 75 - 79
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer George R. Blumenschein Jr.Merrill S. KiesStanley R. Frankel PHASE II STUDIES 25 October 2007 Pages: 81 - 87
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma Karl D. LewisWilliam A. RobinsonRene Gonzalez Phase II Studies 20 September 2007 Pages: 89 - 94
Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity Timothy R. AsmisKi Y. ChungManish A. Shah SHORT REPORT 26 October 2007 Pages: 95 - 96